Organon & Co. (NYSE:OGN) Receives Consensus Rating of “Reduce” from Brokerages

Organon & Co. (NYSE:OGN) has earned an average recommendation of “Reduce” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $8.3750.

Several brokerages have recently weighed in on OGN. Morgan Stanley decreased their price target on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 11th. Piper Sandler cut shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 target price on the stock. in a research note on Monday, October 27th. Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a research report on Wednesday, October 8th. Barclays started coverage on shares of Organon & Co. in a report on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 price target on the stock. Finally, JPMorgan Chase & Co. dropped their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a research note on Tuesday, November 11th.

Institutional Investors Weigh In On Organon & Co.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Hanson & Doremus Investment Management purchased a new position in Organon & Co. in the 2nd quarter worth approximately $26,000. Hantz Financial Services Inc. grew its position in Organon & Co. by 293.8% in the second quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock worth $26,000 after acquiring an additional 1,995 shares in the last quarter. Foster Dykema Cabot & Partners LLC bought a new position in Organon & Co. in the third quarter valued at $29,000. Ransom Advisory Ltd bought a new position in Organon & Co. in the first quarter valued at $32,000. Finally, SouthState Corp raised its position in Organon & Co. by 1,857.0% during the second quarter. SouthState Corp now owns 3,914 shares of the company’s stock valued at $38,000 after purchasing an additional 3,714 shares in the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Stock Down 0.7%

Shares of NYSE OGN opened at $6.97 on Wednesday. The business’s fifty day moving average price is $7.78 and its 200-day moving average price is $9.13. Organon & Co. has a one year low of $6.18 and a one year high of $17.23. The stock has a market capitalization of $1.81 billion, a PE ratio of 3.63, a P/E/G ratio of 1.50 and a beta of 0.57. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20.

Organon & Co. (NYSE:OGN) last issued its earnings results on Monday, November 10th. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.93 by $0.08. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter last year, the business earned $1.38 earnings per share. On average, equities research analysts anticipate that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 11th. Shareholders of record on Thursday, November 20th were issued a $0.02 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $0.08 annualized dividend and a dividend yield of 1.1%. Organon & Co.’s dividend payout ratio (DPR) is presently 4.17%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.